Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproate for the Treatment of Residual Amblyopia
NCT07226141Phase 2Recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Jul 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amblyopia comparing Arm 1 - Placebo first with Arm 2 - Valproate first (2 arms). Primary endpoint: Best-Corrected Visual Acuity at 8 weeks. Started Jul 2026; status: recruiting.
02
Drugs
valproic acid
03
Conditions
amblyopia
Beyond the preview
Go deeper on NCT07226141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226141.